LLY

748.42

+1.7%↑

JNJ

177.03

-0.47%↓

ABBV

209.99

+0.36%↑

UNH

348.72

+8.76%↑

NVO

53.9

-0.77%↓

LLY

748.42

+1.7%↑

JNJ

177.03

-0.47%↓

ABBV

209.99

+0.36%↑

UNH

348.72

+8.76%↑

NVO

53.9

-0.77%↓

LLY

748.42

+1.7%↑

JNJ

177.03

-0.47%↓

ABBV

209.99

+0.36%↑

UNH

348.72

+8.76%↑

NVO

53.9

-0.77%↓

LLY

748.42

+1.7%↑

JNJ

177.03

-0.47%↓

ABBV

209.99

+0.36%↑

UNH

348.72

+8.76%↑

NVO

53.9

-0.77%↓

LLY

748.42

+1.7%↑

JNJ

177.03

-0.47%↓

ABBV

209.99

+0.36%↑

UNH

348.72

+8.76%↑

NVO

53.9

-0.77%↓

Search

Crinetics Pharmaceuticals Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

36.38 3.44

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

34.69

Max

37.19

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-19M

-116M

Pardavimai

670K

1M

Pelno marža

-11,216.004

Darbuotojai

437

EBITDA

-19M

-129M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+102.31% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-11-11

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

275M

2.9B

Ankstesnė atidarymo kaina

32.94

Ankstesnė uždarymo kaina

36.38

Naujienos nuotaikos

By Acuity

4%

96%

2 / 371 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

Crinetics Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-09-08 23:59; UTC

Įsigijimai, susijungimai, perėmimai

Anglo American Is in Talks to Buy Teck Resources, Bloomberg Says

2025-09-08 22:02; UTC

Pagrindinės rinkos jėgos

Microsoft Signs $17.4 Billion AI Deal With Nebius

2025-09-08 17:01; UTC

Pagrindinės rinkos jėgos

Eightco Holdings Stock Surges as Dan Ives Joins Board Amid Crypto Push

2025-09-08 17:01; UTC

Pagrindinės rinkos jėgos

Tron Shares Rise After New Investment From Bravemorning

2025-09-08 16:14; UTC

Pagrindinės rinkos jėgos

Beyond Air Shares Climb on FDA Orphan Drug Designation for Brain Cancer Treatment

2025-09-08 16:13; UTC

Pagrindinės rinkos jėgos

Dianthus Shares Whipsaw on Strong Trial Results, Safety Concerns

2025-09-08 23:12; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-09-08 23:12; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-09-08 23:12; UTC

Rinkos pokalbiai

Infratil's New Bull Likes Exposure to Growing Infrastructure Businesses -- Market Talk

2025-09-08 22:56; UTC

Rinkos pokalbiai

Worst May Be Over for New Zealand Retailers -- Market Talk

2025-09-08 22:23; UTC

Rinkos pokalbiai

Ebos's Near-Term Earnings Outlook Dims -- Market Talk

2025-09-08 21:51; UTC

Rinkos pokalbiai

AT&T Backs Outlook After EchoStar Spectrum Purchase -- Market Talk

2025-09-08 21:47; UTC

Pagrindinės rinkos jėgos

Microsoft Signs $17.4B AI Deal With Nebius

2025-09-08 21:33; UTC

Įsigijimai, susijungimai, perėmimai

This Quantum Pure Play Is Going Public. What Infleqtion Does Differently, Says Its CEO. -- Barrons.com

2025-09-08 21:20; UTC

Įsigijimai, susijungimai, perėmimai

MEG Energy Plans to Respond on or Before Sept 15 >MEG.T

2025-09-08 21:19; UTC

Įsigijimai, susijungimai, perėmimai

MEG Energy Special Committee and Board Will Evaluate Revised Strathcona Offer >MEG.T

2025-09-08 21:18; UTC

Įsigijimai, susijungimai, perėmimai

MEG Energy Acknowledges Strathcona's Intention to Revise Offer

2025-09-08 20:50; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Tech, Media & Telecom Roundup: Market Talk

2025-09-08 19:33; UTC

Rinkos pokalbiai

Oil Futures Gain Despite Planned OPEC+ Output Increases -- Market Talk

2025-09-08 19:22; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Settle Higher -- Market Talk

2025-09-08 19:02; UTC

Rinkos pokalbiai

Dollar Lukewarm Amid Data Hiatus Ahead of August CPI -- Market Talk

2025-09-08 18:24; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-09-08 18:24; UTC

Rinkos pokalbiai

Weaker Argentine Peso Profitable for Grain Producers -- Market Talk

2025-09-08 17:29; UTC

Rinkos pokalbiai

Mexican Inflation Seen Little Changed in August -- Market Talk

2025-09-08 16:59; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

SpaceX Spectrum Acquisition Will Create More Satellite Connection Supply, Verizon CEO Says -- Market Talk

2025-09-08 16:36; UTC

Rinkos pokalbiai

Crude Futures Hold Gains After OPEC+ Output Decision -- Market Talk

2025-09-08 16:20; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2025-09-08 16:16; UTC

Uždarbis

Strategy Stock May Not Ever Make It Into the S&P 500 Index -- Barrons.com

2025-09-08 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-09-08 16:04; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Crinetics Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

102.31% į viršų

12 mėnesių prognozė

Vidutinis 71.09 USD  102.31%

Aukščiausias 97 USD

Žemiausias 36 USD

Remiantis 12 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Crinetics Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

12 ratings

11

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

30.39 / 33.46Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bullish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Neutral Evidence

Rinkos nuotaikos

By Acuity

2 / 371 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
help-icon Live chat